ReviewF1000Research2019
Immunology of membranous nephropathy.
Review in F1000Research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Pragmatic Use of Thyroid Autoantibodies in Clinical Practice: An Update.TouchREVIEWS in endocrinology · 2026Review
- Tiopronin-induced Membranous Nephropathy Presenting with IgG4-predominant Staining Pattern.Internal medicine (Tokyo, Japan) · 2025Article
- Membranous Nephropathy.Journal of clinical medicine · 2025Review
- Article
- Epitope Spreading in Immune-Mediated Glomerulonephritis: The Expanding Target.International journal of molecular sciences · 2024Review
- Erythropoietin Effect on Complement Activation in Chronic Kidney Disease.Biomedicines · 2024Article
- The spatially resolved transcriptome signatures of glomeruli in chronic kidney disease.JCI insight · 2024Article
- The Usefulness of Thyroid Antibodies in the Diagnostic Approach to Autoimmune Thyroid Disease.Antibodies (Basel, Switzerland) · 2023Review
- [Pharmacogenetic testing improves treatment responses in patients with PLA2R-related membranous nephropathy].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2023Article
- Computer-aided diagnosis of primary membranous nephropathy using expert system.Biomedical engineering online · 2023Article
- Article
- Acute chest pain and dyspnoea as clinical presentation of primary membranous nephropathy. A case report and literature review.Acta bio-medica : Atenei Parmensis · 2022Review
- Establishment of Galectin-3 Time-resolved Fluoroimmunoassay and its Application in Idiopathic Membranous Nephropathy.Journal of fluorescence · 2022Article
- MicroRNAs: Potential mediators between particulate matter 2.5 and Th17/Treg immune disorder in primary membranous nephropathy.Frontiers in pharmacology · 2022Article
- Mechanisms of Primary Membranous Nephropathy.Biomolecules · 2021Review
- Membranous nephropathy associated with thrombospondin type-1 domain-containing 7A (THSD7A) in an adult woman with eosinophilia.CEN case reports · 2020Article
- Complement and Complement Targeting Therapies in Glomerular Diseases.International journal of molecular sciences · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accounting for about 20 to 50% of cases of primary nephrotic syndrome, membranous nephropathy (MN) is the leading cause of nephrotic syndrome in adults. A rat model created nearly 60 years ago to research the primary MN disorder, Heymann nephritis, has provided us with a plethora of important information. Recently, our knowledge about MN has dramatically progressed. Heymann nephritis and human MN are now known to share a high degree of similarity in pathogenesis. This review summarizes our current understanding of MN pathogenesis while focusing particularly on the immunological aspects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.